For Q2 FY2026 ended May 31, 2026, Nurix Therapeutics reported revenue of $9.0 million, down 79.5% year-over-year. Net loss was $89.5 million, a 106.0% increase from the prior year. Operating loss was $94.2 million, up 95.0%. Diluted EPS was -$0.81, compared to -$0.52 a year ago. Cash stood at $67.7 million and equity at $402.6 million.
•Revenue fell 79.5% YoY to $9.0 million.
•Net loss widened 106.0% to $89.5 million.
•Operating loss increased 95.0% to $94.2 million.
•Diluted EPS worsened to -$0.81 from -$0.52.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases.
Its portfolio also includes NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies, and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. Incorporated in 2009 and headquartered in Brisbane, California, Nurix Therapeutics was formerly known as Nurix Inc. before rebranding in October 2018.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and antibody therapies for cancer, inflammatory conditions, and other diseases. The company specializes in targeted protein degradation, a novel approach that leverages the body's natural processes to selectively degrade disease-causing proteins. Its lead product candidate is NX-5948, an orally bioavailable BTK degrader currently in Phase 2 clinical trials for relapsed or refractory B-cell malignancies and autoimmune diseases. Additionally, Nurix is developing NX-2127, another BTK degrader in Phase 1a/1b trials for B-cell malignancies, and NX-1607, a CBL-B inhibitor in Phase 1a/1b for immuno-oncology indications. The company also has NX-0479 (GS-6791), an IRAK4 degrader for rheumatoid arthritis and inflammatory diseases, in development.
Where is Nurix Therapeutics (NRIX) listed and in which currency?
Nurix Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol NRIX. The company's shares are traded in US dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Nurix is subject to the reporting and governance requirements of the US Securities and Exchange Commission (SEC). The NasdaqGM is a tier of the Nasdaq stock exchange that includes companies meeting specific financial and liquidity criteria. Investors can buy and sell NRIX shares through brokerage accounts that offer access to US equities, and the stock price is quoted in USD. The company's market capitalization and trading volume are influenced by factors such as clinical trial results, regulatory developments, and broader market conditions in the biotechnology sector.
What sector and industry does Nurix Therapeutics (NRIX) belong to?
Nurix Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Nurix focuses on using biological processes and living organisms to develop therapies for medical conditions. The company's work in targeted protein degradation places it at the forefront of innovative drug discovery approaches. Biotechnology companies like Nurix typically engage in research and development (R&D) to create new drugs, often with a high risk of failure but also the potential for significant rewards if successful. The Healthcare sector encompasses a wide range of companies, including pharmaceuticals, medical devices, and healthcare services. Within this sector, the biotechnology industry is known for its reliance on cutting-edge science, long development timelines, and regulatory hurdles. Nurix's focus on oncology and inflammatory diseases aligns with key areas of unmet medical need.
Where is Nurix Therapeutics headquartered and what is its history?
Nurix Therapeutics is headquartered in Brisbane, California, United States. The company was incorporated in 2009 and was originally known as Nurix Inc. before rebranding to Nurix Therapeutics, Inc. in October 2018. Brisbane is located in the San Francisco Bay Area, a major hub for biotechnology and pharmaceutical innovation. The company's location provides access to a skilled workforce, research institutions, and potential partners. Since its founding, Nurix has focused on developing a pipeline of protein degraders and inhibitors, leveraging its proprietary technology platform. The company has established strategic collaborations with major pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, for co-development and co-commercialization of multiple drug candidates. These partnerships provide financial support and expertise, helping to advance Nurix's programs through clinical development.
What are the main drug candidates in Nurix Therapeutics' pipeline?
Nurix Therapeutics has a pipeline of drug candidates targeting various diseases. The most advanced is NX-5948, an orally bioavailable BTK degrader in Phase 2 clinical trials for relapsed or refractory B-cell malignancies and autoimmune diseases. Another candidate, NX-2127, is also a BTK degrader but is in earlier Phase 1a/1b trials for relapsed or refractory B-cell malignancies. NX-1607 is an orally bioavailable CBL-B inhibitor in Phase 1a/1b for immuno-oncology indications, aiming to enhance the immune system's ability to fight cancer. Additionally, Nurix is developing NX-0479 (also known as GS-6791), an IRAK4 degrader for rheumatoid arthritis and inflammatory diseases. The company has strategic collaborations with Gilead, Sanofi, and Pfizer for co-development and co-commercialization of multiple candidates, which may include these programs. These partnerships help share the costs and risks of drug development while providing access to additional resources and expertise.